The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022.

Friday, November 2, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies

Read the full report: https://www.reportlinker.com/p04974737 The global next-generation antibody therapies market reached $4bn in 2017 and is estimated to reach $17bn by 2023. In
2017, the antibody-drug conjugates segment held 45% of the global next-generation antibody therapies market.How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.In this brand new 217-page report you will receive 141 charts– all unavailable elsewhere.The 217-page report provides clear detailed insight into the next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.By ordering and reading our brand-new report today you stay better informed and ready to act.Report Scope- Global Next-Generation Antibody Therapies Market from 2018-2028Forecast of the Global Next-Generation Antibody Therapies market by Submarket:- Antibody Fragments & ALPs- Antibody-Drug Conjugates- Biosimilar Antibodies- Bispecific Antibodies- Engineered AntibodiesForecast of the Global Antibody Fragments & ALPs submarket by Product:- Kalbitor- Other Antibody FragmentsForecast of the Global Antibody-Drug Conjugates submarket by Product:- Adcetris- Kadcyla- Mylotarg- Other ADCsForecast of the Global Biosimilar Antibodies submarket by Product:- Infliximab- Adalimumab- Rituximab- Bevacizumab- Trastuzumab- Other Biosimilar mAbsForecast of the Global Bispecific Antibodies submarket by Product:- Blincyto- Hemlibra- Other Bispecific AntibodiesForecast of the Global Engineered Antibodies submarket by Product:- Gazyva/Gazyvaro- Poteligeo- Fasenra- Other Engineered AntibodiesThis report provides individual revenue forecasts to 2028 for these regional and national markets:- North America: US, Canada, and Mexico- Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe- Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific- LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEAOur study discusses the selected leading companies that are the major players in the next-generation antibody therapies market:- Amgen, Inc.- GlaxoSmithKline (GSK)- Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.)- Merck KGaA- Novartis AG- Pfizer, Inc.- Roche- Sanofi- Seattle Genetics, Inc.- Shire plc- This report discusses SWOT & STEP analysis of the next-generation antibody therapies market as well as factors that drive and restrain this market. This report also discusses the opportunities that can be tapped in this market.- This report also discusses selected at that are in the pipeline.Read the full report: https://www.reportlinker.com/p04974737 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-global-acute-myeloid-leukaemia-market-reached-1bn-in-2017-and-is-estimated-to-reach-2-8bn-by-2022--300742362.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store